Osiris Therapeutics Company Profile

21:56 EDT 21st March 2019 | BioPortfolio

Leading the way to a better tomorrow Osiris Therapeutics, Inc. is a company founded to commercialize stem cell products from adult bone marrow. These stem cells have demonstrated the ability to repair different types of tissues. The next revolution in medical care Osiris Therapeutics is commercializing products from a readily available and non-controversial source – adult bone marrow. These stem cells have demonstrated the ability to repair different types of tissue and offer a very real opportunity to develop revolutionary new treatments for certain disease processes including autoimmune disorders, heart attacks and arthritis. Osiris’ technology is based on the pioneering work of Dr. Arnold Caplan and his colleagues at Case Western Reserve University. They showed that Mesenchymal Stem Cells (MSCs) can engraft and selectively differentiate, based on the tissue environment, to such lineages as muscle, bone, cartilage, marrow stroma, tendon and fat. Due to their cellular origin and phenotype, these cells do not provoke an immune response, allowing for the development of products derived from unrelated human donors.


2001 Aliceanna Street
United States of America


Phone: 410 522 5005
Fax: 410 522 6999

News Articles [814 Associated News Articles listed on BioPortfolio]

Osiris Therapeutics Names Samson Tom CEO

WASHINGTON (dpa-AFX) - Osiris Therapeutics Inc. (OSIR), Monday said it has appointed Samson Tom to serve as President and Chief Executive Officer, effective November 26, 2018.Tom was at Osiris fro...

Smith & Nephew agrees to buy Osiris Therapeutics for $660m

Based in Columbia of Maryland, Osiris Therapeutics is engaged in the development, manufacturing and commercialization of regenerative medicine products such as skin, bone graft and articular cartilage...

Osiris Therapeutics Inc. Announces Drop In Q3 Earnings

WASHINGTON (dpa-AFX) - Osiris Therapeutics Inc. (OSIR) revealed a profit for third quarter that dropped from the same period last year.The company's profit came in at $4.21 million, or $0.12 per s...

Smith & Nephew to pay around $660M for Osiris Therapeutics

Smith & Nephew has agreed to pay about $660 million for regenerative medicine firm Osiris Therapeutics.  -More- 

Smith & Nephew buys Osiris in regenerative medicine push

Medical equipment company Smith & Nephew has agreed a $660 million deal to buy US biotech Osiris Therapeutics that expands its business into regenerative medicine. Osiris makes medical products u...

Smith & Nephew To Acquire Osiris Therapeutics In $660 Mln Deal

LONDON (dpa-AFX) - Smith & Nephew plc (SNN,SN.L) said that it has agreed to acquire Osiris Therapeutics, Inc. (OSIR)for $19.00 per share in cash, representing a total equity value of about $660 mi...

Osiris Therapeutics Announces GrafixPL PRIME Launches October 1, 2018

Osiris Therapeutics (NASDAQ:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announces that GrafixPL PRIME™, a h...

Smith & Nephew buys Osiris Therapeutics in deal valued at $660mm

Expanding its wound healing and tissue repair portfolio, Smith & Nephew PLC is paying $19 per share in cash (a 7% premium based on the 10-day market average) to acquire regenerative medicines firm Osi...

Drugs and Medications [27 Associated Drugs and Medications listed on BioPortfolio]

Kynamro [kastle therapeutics, llc]


Olopatadine hydrochloride [somerset therapeutics, llc]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

Oxygen [breathe easy therapeutics, inc]


Diclofenac sodium delayed release [cambridge therapeutics technologies, llc]

Diclofenac Sodium

Olopatadine hydrochloride [a-s medication solutions]

OLOPATADINE Hydrochloride Ophthalmic Solution USP, 0.1%Somerset Therapeutics, LLC

PubMed Articles [458 Associated PubMed Articles listed on BioPortfolio]

Open-label Extension Phase of a Chronic Diabetic Foot Ulcer Multicenter, Controlled, Randomized Clinical Trial Using Cryopreserved Placental Membrane.

The results of the single-arm, open-label extension phase of the Grafix (cryopreserved placental membrane; CPM; Osiris Therapeutics, Inc, Columbia, MD) multicenter, blinded, randomized, controlled cli...

The use of fast photochemical oxidation of proteins coupled with mass spectrometry in protein therapeutics discovery and development.

Structural analysis of protein therapeutics is a challenging task owing to complexities associated with large molecular size and 3D structures. Recent advances in fast photochemical oxidation of prote...

Biologics for the treatment of noninfectious uveitis: current concepts and emerging therapeutics.

There is mounting evidence supporting the use of biologic therapeutics for the management of noninfectious uveitis (NIU). This review highlights: biologics with documented efficacy in NIU; agents with...

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

CRISPR: a promising tool for lipid physiology and therapeutics.

The purpose is to review recent progress in applying the CRISPR/Cas9 system to lipid metabolism and therapeutics.

Clinical Trials [175 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1311 Associated Companies listed on BioPortfolio]

Osiris Therapeutics, Inc.

Osiris Therapeutics, Inc. is the leading stem cell therapeutic company focused on developing products to treat serious medical conditions in the inflammatory, autoimmune, orthoped...

Osiris Therapeutics

Leading the way to a better tomorrow Osiris Therapeutics, Inc. is a company founded to commercialize stem cell products from adult bone marrow. These stem cells have demonstrated the ability to repair...

Spencer Trask

Spencer Trask develops innovative ideas into world-changing companies. The company is the legacy of Mr. Spencer Trask, the financier who backed Thomas Edison and invested in the light bulb, the first...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Osiris Therapeutics" on BioPortfolio

We have published hundreds of Osiris Therapeutics news stories on BioPortfolio along with dozens of Osiris Therapeutics Clinical Trials and PubMed Articles about Osiris Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Osiris Therapeutics Companies in our database. You can also find out about relevant Osiris Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Corporate Database Quicklinks

Searches Linking to this Company Record